The mood stabilizing agents lithium chloride (LiCl) and sodium valproate (VPA) have recently gained interest as potential neuroprotective therapeutics. However, exploitation of these therapeutic applications is hindered by both a lack of molecular understanding of the mode of action, and a number of sub-optimal properties, including a relatively small therapeutic window and variable patient response. Human neuroblastoma cells (SH-SY5Y) were exposed to 1 mM lithium chloride or 1 mM sodium valproate for 6 h or 72 h, and transcriptomes measured by Affymetrix U133A/B microarray. Statistically significant gene expression changes were identified using SAM software, with selected changes confirmed at transcript (TaqMan) and protein (Western blotting) levels. Finally, anti-apoptotic action was measured by an in vitro fluorescent assay. Exposure of SH-SY5Y cells to therapeutically relevant concentrations of either lithium chloride or sodium valproate elicited 936 statistically significant changes in gene expression. Amongst these changes we observed a large (maximal 31.3-fold) increase in the expression of the homeodomain protein Six1, and have characterized the time-and dose-dependent up-regulation of this gene in response to both drugs. In addition, we demonstrate that, like LiCl or VPA treatment, Six1 over-expression protects SH-SY5Y cells from staurosporine-induced apoptosis via the blockade of caspsase-3 activation, whereas removal of Six1 protein via siRNA antagonises the ability of LiCl and VPA to protect SH-SY5Y cells from STS-induced apoptosis. These results provide a novel mechanistic rationale underlying the neuroprotective mechanism of LiCl and VPA, suggesting exciting possibilities for the development of novel therapeutic agents against neurodegenerative diseases such as Alzheimer's or Parkinsonism.
Introduction
Lithium chloride (LiCl) and the anticonvulsant valproate (VPA) are frontline treatments for the manic phase of bipolar disorder (BD), acting as mood stabilizers (McElroy et al., 1992) . The quoted prevalence for BD is approximately one percent of the population (Spearing, 2001) , although several factors probably result in under-or misdiagnosis. First, there are many BD phenotypes, complicating diagnosis (Thomas, 2004; MacQueen et al., 2005) . Second, from these multiple phenotypes several variants exist in which one or other phase is extremely mild. Third, the combination of the previous two factors result in frequent incorrect diagnosis of BD as unipolar disorder (Dunner, 1992; Spearing, 2001) meaning that the actual prevalence may be considerably higher. In addition to this established therapeutic area, increasing support is being given towards the use of LiCl and VPA as general neuroprotective agents, with potential treatments including disorders such as Alzheimer's or Parkinsonism (Brunello, 2004; Aghdam and Barger, 2007) , although the molecular rationale behind this has yet to be elucidated (Di Daniel et al., 2005) . This combined therapeutic arena, encompassing both mood stabilization and neuroprotection means that the potential patient population who may be subject to chronic treatment with these therapeutic agents is very large. Unfortunately, in addition to possessing unknown molecular mode of action(s), both LiCl and VPA have several other sub-optimal parameters. First, for treatment of bipolar disorder only around 50 % of patients respond to LiCl therapy and a similar number (54 %) to VPA treatment (Mendlewicz et al., 1999) . Second, both LiCl and sodium valproate have relatively small therapeutic indices (Strakowski et al., 2001) . Third, both LiCl and VPA require high dosing levels (millimolar circulating concentrations) to achieve efficacy (Jann et al., 1982; Balfour and Bryson, 1994) . It is thus clear that in order to optimize the use of these agents and/or develop novel therapeutics it is necessary to fully understand their molecular actions.
Both LiCl and VPA, along with other mood stabilizing agents, elicit wide-ranging effects on neural cells, including a shared ability to protect against apoptotic insults (Chuang, 2004) . Several investigations have suggested that inhibition of glycogen synthase kinase 3 beta (GSK3?) is a central component to both their mood stabilization and neuroprotective abilities (Bijur and Jope, 2000; Li et al., 2002b) . However, other studies have proposed mechanisms centred around p53 modulation (Lu et al., 1999) , phosphatidyloinositol signalling (Ding and Greenberg, 2003) , histone deacetylase inhibition (Phiel et al., 2001) or endoplasmic reticulum dysfunction (Kim et al., 2005) . There is thus a need for further studies to understand how these individual effects combine to produce the known phenotypic effects of these agents.
To begin to understand the molecular mode of action of both LiCl and VPA in neural cells we have used DNA microarray analysis to examine changes in the transcriptome of human SH-SY5Y neuroblastoma cells in response LiCl and VPA. Concentrations used were within the therapeutic range, with patient serum levels range from 0.8-2 mmol/L for LiCl (Sproule, 2002) and 0.3-0.8 mmol/L for VPA (Allen et al., 2006) , with brain concentrations expected to be similar due to the good ability of both compounds to cross the blood-brain barrier. Both agents elicit a marked rise in the expression of the cell differentiation factor Six1, and we demonstrate that this increase is central to the ability of both LiCl and VPA to exert their neuroprotective effect.
Methods and Materials
Cell Culture SH-SY5Y cells (ECACC 94030304), a human neuroblastoma cell line, were obtained from ECACC (Porton Down, Wilts, UK) and Bristol University. Cells were routinely cultured in DMEM:F12 supplemented with 10% foetal calf serum, 50 U/ml penicillin and 50 ?g/ml streptomycin. All cell culture consumables were purchased from Invitrogen (Paisley,UK).
As indicated, a Six1 expression plasmid, or control plasmid, was transfected into SH-SY5Y cells using FuGENE 6 (Roche Diagnostics, Lewes, UK), along with a GFP expression plasmid (BD Biosciences) to act as an internal control. Cells were then incubated for 48 hours before the addition of 1 ?M STS (STS) for 16 hours
For siRNA experiments pre-designed Six1 silencer siRNA (Ambion, Warrington, UK) was transfected into cells using the Silencer siRNA transfection system (Ambion) as per manufacturer's recommendations, with two separate siRNAs against Six1 used to ensure specificity of response. In addition, a pre-designed silence siRNA against HCaRG was used to control for off-target effects. DNA Microarray and Analysis SH-SY5Y cells were seeded at 2.4 x 10 5 cells/cm 2 in 25 cm 2 flasks and allowed to attach overnight. Cells were dosed daily with 1 mM lithium chloride (Sigma Aldrich, Poole, UK), 1 mM sodium valproate (Sigma Aldrich) or medium control. Following 6 or 72 hours of exposure, total RNA was isolated from quadruplicate samples using the RNeasy Mini kit (Qiagen, Crawley, UK) and was quantified using a Nanodrop Agilent 2100 Bioanalyser. Medium was changed 6 hours prior to the 72 hour time point to control for gene expression elicited by medium shock. In addition, the quadruplicate biological samples were composed of two samples each from the ECACC and Bristol-sourced SH-SY5Y cells; sourcing cells from two different sites controls for site-specific phenotypic changes in cell lines that can potentially obscure the biologically relevant changes.
Samples were used to interrogate the Affymetrix U133A/B GeneChip set, representing over 47,000 transcripts including approximately 38,500 fully annotated probe sets.
The data generated from the microarray analysis was first normalised using the Affymetrix algorithm that allows reliable comparison of multiple arrays, minimising differences of nonbiological origin. Next the SAM (Significance Analysis of Microarrays) package (http://wwwstat.stanford.edu/~tibs/SAM/) was used to identify significantly altered gene expressions, and generate false discovery rate (FDR) values for the analysis. The SAM package offers the advantage over other microarray analysis tools in that it does not presume equal variance or independence of genes (or both), scenarios that are often violated in biological systems (Tusher et al., 2001) . SAM settings were for a two class unpaired analysis between, using one hundred permutations to calculate the differentially expressed gene list. No fold-change threshold was set, with instead the delta function manually altered to provide a false discovery rate of approximately 1 %. The exception to this is for 72 hours exposure to LiCl, where a false discovery rate of 20 % was used due to the very low number of differentially expressed transcripts identified when lower FDRs were used. To examine the potential impact on biological pathways of the identified gene expression changes the DAVID software suite (http://david.abcc.ncifcrf.gov/home.jsp) was used to undertake functional annotation clustering, whereby GO identifiers that are statistically overrepresented are clustered according to their biological functions (Dennis Jr et al., 2003) .
Transcript level measurement
Primers and TAMRA/FAM dual labelled probe specific for Six1, Bcl2, Bcl2L1 and 18S were designed using the Primer Express software (Applied Biosystems, Warrington, UK) and were purchased from MWG (Milton Keynes, UK).
SH-SY5Y cells were seeded at 2.4 x 10 5 cells/cm 2 in 25 cm 2 flasks and allowed to attach overnight. Cells were dosed daily with either varying concentrations of lithium chloride, sodium valproate or medium control. At specified time points, total RNA was isolated from quadruplicate samples using the RNeasy Mini kit (Qiagen) and was quantified using a Nanodrop Agilent 2100 Bioanalyser.
Total RNA was treated with RNase-free DNase (Promega, Southampton, UK) to remove genomic contamination. Reverse transcription was primed with random hexamers and carried out by Superscript II (Invitrogen) as per the manufacturer's instructions. To ensure that DNase treated samples were free from genomic contamination an RT-control (lacking enzyme) was carried out for every RNA sample. cDNA generated from 50 ng (Six 1) or 50 pg (18S rRNA) of total RNA was amplified using TaqMan Universal PCR Master Mix with 400 nM primers and 200 nM fluorogenic probe in a total reaction volume of 25 µl. Quantitative polymerase chain reaction (Q-PCR) reactions were run on the ABI7000 SDS instrument and quantitation was carried out using the ABI proprietary software against a standard curve generated from human genomic DNA (Promega). Protein level measurement SH-SY5Y cells were seeded at 2.4 x 10 5 cells/cm 2 in 25 cm 2 flasks and allowed to attach overnight. Cells were dosed daily with either varying concentrations of lithium chloride, sodium valproate or medium control. Following 72 hours of exposure total protein was extracted in RIPA buffer (1xPBS pH 7.3, 1% Nonidet P40, 0.5 % sodium deoxycholate, 0.1 % SDS), with 1x protease inhibitor cocktail solution (Roche, Lewes, Sussex, UK) added just prior to use.
Total SH-SY5Y protein extracts (5 (g per lane) were resolved on 12 % SDS-polyacrylamide gels and then transferred electrophoretically to Hybond ECL nitrocellulose membranes (Amersham Biosciences, Little Chalfont, Bucks, UK). Membranes were blocked (1 hour) in 5 % fat free dried milk and then probed with primary antibodies against Six1 (sc-9127; 1:400), cylcinA1 (sc-15383; 1:300) or pax3/7 (sc-7748; 1:300) for one hour (Autogen Bioclear, Calne, Wilts, UK), followed by anti-rabbit (Six1/CyclinA1; sc-2007; 1:5000) or anti-goat (Pax3/7; sc-2022; 1:5000) IgG for one hour (Autogen Bioclear). Bound antibodies were visualised using enhanced chemiluminescence reagents according to the manufactures instructions (Amersham Biosciences), and opposed to Fuji Super RX film (Fisher Scientific). Computer based densitometry of gels was undertaken using a GeneGenius Bioimaging System (Syngene, Frederick, MD). Immunoblots were also probed with an antibody against ?-actin (ab-8226; 1:1000) for one hour (AbCam, Cambridge, UK), followed by anti-mouse IgG (ab-6728; 1:2000) for one hour (AbCam) to ensure even loading per lane.
The phosphorylation status of GSK3? within cells was determined using the phosphoELISA assay (Invitrogen) according to the manufacturer's instructions. Briefly, cells were grown as described above and extracted into RIPA buffer. pTyr216GSK3? was measured as a marker of the active enzyme, while pSer9GSK? was measured as a marker of inactive protein.
Cell Death Measurement
SH-SY5Y cells were seeded at 2.4 x 10 5 cells/cm 2 in 25 cm 2 flasks and allowed to attach overnight. For the last 16 hours of cell treatment, cells were exposed to 1 µM staurosporine (STS), as indicated, to induce apoptosis. Cell Death was measured by LDH-leakage using the cytotoxicity detection kit (Roche), as per the manufacturer's instructions. LDH measurements were normalised to medium-only (0 % cell death) and 0.1 % (v/v) Triton X100-lysed cells (100 % cell death). Caspase-1 and Caspase-3 activity was measured using the CaspACE assay system (Promega), according to the manufacturer's instructions. Briefly, following exposure to STS, cells were washed in PBS, resuspended in hypotonic lysis buffer (25 mM HEPES, pH 7.5, 5 mM MgCl 2 , 5 mM EDTA, 5 mM DTT, 1x protease inhibitor cocktail (Roche)) and lysed by four cycles of freeze-thaw, followed by centrifugation at 16,000 g for 20 minutes at 4 (C. Supernatants were mixed with specific fluorogenic substrates (Ac-DEVD-AMC or Ac-YVAD-AMD for caspase-3 and -1 respectively), incubated for 1 hour at 30 (C, and then substrate turnover measured using a Molecular Dynamics SpectraMax Gemini XS with excitation and emission wavelengths of 360 nm and 460 nm respectively.
Results

Microarray analysis of SH-SY5Y transcriptome following exposure to LiCl or VPA
Exposure of SH-SY5Y cells to mood stabilizing agents for 6 hours provides information on genes whose expression are likely to be affected directly by the action of LiCl and VPA (i.e. primary targets). In comparison, exposure to LiCl and VPA for 72 hours provides a measure of transcriptome changes caused by both direct and indirect effects of these chemicals on the SY-SY5Y transcriptome. SH-SY5Y cells from two different sources were used in the microarray experiment to control for potential source-specific phenotypes that could act as confounders to interpretation of the data. Correlation analysis between the transcriptome of the ECACC-and Bristol-sourced SH-SY5Y control cultures showed no significant variance at either the 6 or 72 hours time points ( Figure 1A ). Following exposure of cells to either LiCl or VPA the transcriptomes were still highly correlated (r 2 >0.98 in all cases), and hence results from ECACCand Bristol-sourced SH-SY5Y cells were pooled for microarray analysis, increasing the power of the experiment. Figure 1B -E shows the Significance Analysis of Microarrays (SAM) output plot for each of the test conditions, with the correlation analysis between the two cell sources included as an inset. Each SAM plot details the number of altered genes identified for the specified False Discovery Rate (FDR), with more detailed information on the number and direction of these changes is provided in table 1. It can be seen that at a therapeutically relevant, equimolar, concentration (1 mM) VPA has a much larger impact on the SH-SY5Y transcriptome compared to LiCl, with VPA elicited 922 changes compared to only 14 changes elicited by LiCl. The full list of altered genes is presented as supplementary information. As no significant difference in transcriptome response was observed between ECACC-and Bristol-sourced cells in response to either LiCl of VPA exposure the ECACC-sourced cell line was chosen for all subsequent experiments due to its increased general availability.
A further refinement of transcriptome analysis was undertaken using the DAVID bioinformatic suite to interrogate Gene Ontology (GO) identifiers of transcripts altered by chemical treatment. As GO identifiers refer to biological processes rather than individual reactions any over-representation in a dataset is often indicative of a significant impact on the pathway(s) associated with the GO identifiers. Table 2 shows the main GO identifiers shown to be overrepresented in the microarray data, with the number of genes associated with each treatment/GO identifier indicated. SH-SY5Y exposure to VPA elicited the largest number of significantly overrepresented GO identifiers, consistent with the larger number of genes altered by this drug in comparison to LiCl. In general, GO identifiers over-represented after 6 hours were also seen at 72 hours, but with more altered genes associated with them, a logical consequence of a more developed biological response to chemical exposure. The exception to this are the GO identifiers grouped under 'cell communication', which generally decline in number between the early and late time points of the microarray analysis. This is perhaps not unsurprising given that transmission of cellular signals should logically occur early in a response, with endpoint changes such as metabolic capacity occurring later, possibly as a result of these signalling pathways. LiCl and VPA alter Six1 expression in SH-SY5Y cells Amongst those genes whose expression was altered by VPA exposure, the homeobox gene sine oculis 1 (Six1) showed one of the largest changes, being up-regulated by 31.3 fold following 72 hours of exposure. Examination of the microarray dataset revealed that LiCl also caused a statistically significant increase in Six1 gene expression although to a smaller magnitude, being 1.7 fold by 72 hours. Due to this small fold-change, Six1 does not appear in the list of LiClaltered genes presented as supplementary material, being one of those within the false negative group. To correctly identify Six1 as being significantly increased within this group would require an FDR of 83.5 %, resulting in an unacceptably high number of false positives. Gene expression of Six1 is not significantly altered by 6 hours treatment with either LiCl or VPA, suggesting that the affect is due to an indirect action of these agents on Six1 expression
To confirm and further characterize this change, we next examined the time and dose response of compound-mediated increases in Six1 transcript levels by TaqMan Q-PCR. Both VPA and LiCl elicited a dose-dependent increase in Six1 transcript level (Figure 2a) , and as observed with the microarrays, VPA elicited the larger fold-increase in transcript level (6.8 fold) compared to LiCl (3.7 fold). Figure 2b demonstrates that the observed increase in transcript levels was mirrored at the protein level, with 48 hours exposure resulting in significant increases in Six1 protein levels. Specific identification of the Six 1 immunoreactive band was confirmed through comparison to recombinant Six1. The Six1 antibody used, targeted against amino acids 1-444 of the protein, detects several other immunoreactive bands and it is possible that these correspond to different phosphorylation states of Six1, or to other members of the Six family. As the immunoreactive bands are of sizes comparable to other members of the Six family this would support the latter scenario, and interestingly several of these also alter following compound treatment. The induction of Six1 transcript levels in SH-SY5Y cells occurs more rapidly following exposure to VPA, reaching significance within 18 hours, whereas LiCl exposure required 48 hours exposure to elicit a statistically significant increase (Figure 2c) . A larger fold increase in Six1 expression is observed following 48 hours treatment with 3mM VPA, approximately 32-fold, compared to that seen in figure 2a, which is approximately 7-fold. However this difference is due to a difference in the basal expression of Six1, with the induced level being approximately 2000 transcripts/ng input RNA in both cases. Both agents are seen to elicit a response only following a sub-acute exposure, in agreement with the microarray data, and this is suggestive that the effect of these agents on Six1 gene expression occurs via an indirect mechanism. Six1 contributes to the anti-apoptotic effects of LiCl and VPA The classical apoptosis-inducting chemical STS was capable of causing 92 % cell death in SH-SY5Y cells (Figure 3a) , and this was accompanied by an increase in caspase-3 activity (205 % of control), but no change in caspase-1 activity (Figure 3b ). Pre-exposure of SH-SY5Y cells to the anti-mania drugs VPA and LiCl for 48 hours provided partial protection against STS (STS)-mediated cell death, and reduced the activation of capase-3 to 145 % and 158 % of control levels respectively (Figure 3a+b) .
In order to investigate potential mechanisms by which this effect could be mediated we undertook pathway analysis using PathwayArchitect, constructing the model presented in figure  3c . In this model, both LiCl and VPA interact with GSK3?, inhibiting its action. One of the many cellular targets for GSK3? is beta-catenin, and hence inhibition of GSK3? would lead to an accumulation of beta-catenin, which in turn activates the expression of a number of factors including the transcription factor Pax3, a factor that has previously been linked to the Six family. A downstream target for Six1 is cyclinA1, and we hypothesize that increases in Pax3 and cyclinA1 would result in increased expression of the anti-apoptotic factors Bcl2L1(Bcl-xl) and Bcl2 respectively, resulting in the observed protection from STS-induced apoptosis.
To test this hypothetical pathway, we next examined the effect of LiCl and VPA exposure of SH-SY5Y cells on the expression of factors identified within the hypothetical pathway presented in figure 3c . Exposure of SH-SY5Y cells to either LiCl or VPA resulted in a dose-dependent inhibition of GSK3? (figure 4a), as measured by decreased pTyr216-GSK3? (active form) and increased pSer9-GSK3? (inactive form). Protein levels of Pax3 and cyclinA1 were increased by both LiCl and VPA in a dose-dependent manner (Figure 4b ). Up-regulation of Pax3/cyclinA1 is proposed to result in increased levels of the anti-apoptotic proteins Bcl2 and Bcl2L1, and figure 4c demonstrates the increased transcript levels for these factors in SH-SY5Y cells following exposure to LiCl or VPA.
Next, the input of Six1 into the observed neuroprotective effect was examined through overexpression and knock-down experiments. Over-expression of Six1 reduced STS-induced cell death in SH-SY5Y cells by 43 %, and this reduction was again associated with an 8 % decrease in the activation of caspase-3 (Figure 5a+b ). This protection from STS-induced apoptosis is not complete however, demonstrating that other mechanisms also contribute to STS-induced apoptosis, as reviewed by Gurvich and Klein (Gurvich and Klein, 2002) .
Finally, SH-SY5Y cells were transiently transfected with siRNA targeted against Six1, and then exposed to either VPA or LiCl for 48 hours. Under such a treatment regime, increased expression of Six1 by compounds was reduced to 131 % and 238 % of control for LiCl and VPA respectively, compared to 290 % and 878 % without Six1 siRNA treatment (Figure 5c ). This repression was confirmed as specific through the use of both a second siRNA targeted against Six1, which gave a similar level of knock-down (data not shown). Such data demonstrates that siRNA treatment was capable of reducing Six1 transcript expression in the cells by up to 73 %, although further work would be required to show that this effect translated to protein levels. As previously seen, in cells exposed to LiCl or VPA alone, STS exposure results in significantly decreased cell death compared to STS alone (24 % and 27 % respectively; Figure 5d ). Over expression of Six1 in SH-SY5Y cells results in an approximately 20% antagonism of the ability of LiCl or VPA to protect cells from STS-induced apoptosis (Figure 5d ). Transfection of SH-SY5Y cells with a non-Six1 siRNA, active against hypertension related, calcium regulate gene (HCaRG), demonstrated that the observed effect was specific and as a result of off-target effects (Figure 5d ). Taken together, such data is strongly supportive of Six1 being the central component in the ability of LiCl and VPA to inhibit STS-induced apoptosis.
Discussion
The Six family of proteins are vertebrate homologues of the Drosophila sine oculis proteins, which are involved in cell fate differentiation (Kawakami et al., 2000) . Sine oculis family members interact with the eyeless, eyes absent and dachshund proteins and are central to Drosophila eye development (Serikaku and O'Tousa, 1994) , while their mammalian homologues (Six1-6, Pax, Eya and Dac respectively) have also been shown to play an important role in organogenesis (Li et al., 2003; Xu et al., 2003; Zheng et al., 2003) . Their expression in specific migrating cell populations appear to be vital, as both Drosophila and mice null for Six1 are nonviable, with null mice exhibiting large scale abnormalities in the development of skeletal muscle, as well as several major organs (Serikaku and O'Tousa, 1994; Laclef et al., 2003) . Beyond this initial identification as crucial regulators during development, six family members have recently come under the spotlight due to their potential role in tumourogenesis, which is perhaps not Plant et al: Six1 mediates LiCl/VPA-induced neuroprotection surprising given their established role in cell migration and differentiation. Six1 has been shown to regulate cellular proliferation at the G2-M checkpoint (Ford et al., 1998; Ford et al., 2000) , to be over-expressed in a number of tumours (Ford et al., 1998; Li et al., 2002a; Reichenberger et al., 2005) , inhibit apoptosis within ovarian tumours (Behbakht et al., 2007) , and has been shown to be involved in metastasis (Yu et al., 2004) . A common feature of tumour development is often the co-ordinate regulation of both cell proliferation and apoptosis, with up-regulation of the former and inhibition of the latter being central to mutation fixation and tumour growth (Roberts et al., 1995; Plant et al., 1998; Pliskova et al., 2005) . It is thus interesting that GO analysis clearly shows that genes associated with both apoptotic cell death and cell cycling are affected by VPA treatment. Genes up-regulated by 72 hours VPA treatment include several genes implicated in the inhibition of apoptosis, including pim-1 (Moroy et al., 1993) , BAG3 (Silva et al., 2008) , inhibin ?a (Denkova et al., 2004) , as well as those associated with growth arrest, including p21 (Wakabayashi et al., 2000) and GAS2 (Brancolini et al., 1995) . Such statistical analysis of GO identifier over-expression does not identify the extent of impact on a biological pathway, merely that more genes in that pathway are altered than would be expected by chance. This is exemplified by the fact although GO identifiers negative regulation of apoptosis/cell cycling are over-represented in the genes up-regulated following VPA exposure so are genes associated with positive regulation, including TGF? (Bursch et al., 1993) and FOXO1 (Fukunaga et al., 2005) . Such data is consistent with studies showing that VPA can elicit either pro-apoptotic (Phillips et al., 2003; Chen et al., 2007) or anti-apoptotic (Brunello, 2004) responses, with cellular fate presumably being determined by the net flow through these two opposing pathways under any particular cell/species/biological condition. Herein we demonstrate that exposure of SH-SY5Y cells to VPA has an inhibitory effect on apoptosis, reducing STSmediated cell death, suggesting that in this case the net flow is through the anti-apoptotic pathway. STS-mediated cell death has previously been shown to occur through the activation of caspase-3 in SH-SY5Y cells (Posmantur et al., 1997 ), and we demonstrate that both LiCl and VPA partially protect (40-50 %) cells from STS through the inhibition of caspase-3 activity.
The molecular mechanisms underlying the many effects of LiCl and VPA on neural cells have not been fully elucidated at present. In the current study VPA elicited many more alterations to the SHY-SY5Y transcriptome compared to LiCl, and two potential explanations exist for this. First, daily dosing of chemicals could have resulted in accumulation of VPA within cells, effectively increasing the exposure. However, daily dosing was specifically chosen due to the relatively short half-life of VPA in culture, approximately 4.5 hours, to ensure an even exposure was obtained. LiCl has a considerably higher half-life in culture (approximately 30 hours), but the evidence presented herein is not consistent with an over-exposure to this agent. Second, VPA has a recognised action as a histone deacetlylase (HDAC) inhibitor (De Sarno et al., 2002) , which could potentially result in a more wide-spread transcriptome effect following exposure. Indeed, recent work has suggested that the HDAC-inhibitory action of VPA is, at least in part, responsible for the neuroprotective mechanisms of this chemical (Chen et al., 2007; Kim et al., 2007; Leng et al., 2008) .
A common action of both chemicals in neural cells appears to be inhibition of GSK3?, although this is caused by different mechanism by the two agents. LiCl is a direct inhibitor of GSK3? through altered phosphorylation, whereas VPA appears to act both directly and indirectly via its HDAC inhibitory action (Chen et al., 1999a; De Sarno et al., 2002; Al-Assar and Crouch, 2005 ). Herein we demonstrate that in human SH-SY5Y cells both LiCl and VPA are able to inhibit GSK3? activity, which is in line with previous work in this cell line (De Sarno et al., 2002) . Both agents produce a dose-dependent decrease in the active pTyr216-GSK3?, while increasing pSer9-GSK3? by up to 300 %. A multitude of biological roles have been identified for GSK3? (Jope and Johnson, 2004) , and hence it is not a simple process to understand the consequences of GSK3? inhibition by LiCl and VPA. Increased levels of GSK3? have been associated with increased apoptosis in SH-SY5Y cells (Bijur and Jope, 2000) and ultimately neurodegeneration in mice (Lucas et al., 2001) , and hence this has led to the suggestion that GSK3? inhibition may play a role in the known neuroprotective actions of both LiCl and VPA in humans (Brunello, 2004 ). Herein we confirm that both LiCl and VPA are able to protect neural cells from STS-mediated cell death, and show that this is due to decreased activity of caspase-3. Over-expression of Six1 in SH-SY5Y cells only results in an 8 % decrease in capase-3 activity following STS exposure, but this is accompanied by a 42 % decrease in cell death. The explanation for this disparity is not clear, but may be a reflection of the sampling time point (16 hours of STS exposure), at which point many cells will be committed to, or have undergone, cell death and hence caspace-3 measurements are an underestimate. In addition, we present evidence to support a novel molecular pathway downstream of GSK3? inhibition that could mediate this effect. This model has been generated through a text-mining approach, whereby interactions between proteins, regardless of species or tissue of origin, are organised into a network. Whereas this has the advantage that it can utilise a large literature base for construction of the pathway, it is important to note that as species-and/or tissue-specific signalling pathways may exist the generated pathway must be confirmed experimentally in the tissue of interest. The degradation of beta-catenin is controlled by GSK3? in a host of cell types, including neurons (Novak and Dedhar, 1999; Kimelman and Xu, 2006) , and hence inhibition of GSK3? would lead to an accumulation of beta-catenin target genes. Amongst these targets is the transcription factor Pax3, which has previously been shown to regulate transcription of Six1 in murine embryonic cardiomyocytes (Petropoulos and Skerjanc, 2002) , with both Pax and Six family members being central to murine neural development (Wlodarczyk et al., 1996) . Herein we demonstrate that LiCl and VPA treatment results in increased protein levels of Pax3, Six1 and cyclinA1 in human neuroblastoma cells. Whereas we do not demonstrate a causal relationship between the increase in these protein levels in the current work, the previously demonstrated inter-relationships of Pax3 and Six1 (Petropoulos and Skerjanc, 2002) and the interaction of Six1 and CyclinA1 in murine embryonic fibroblasts (Coletta et al., 2004) suggest that one may exist, allowing us to present the hypothetical pathway shown in figure 3. Pax3 and cyclinA1 have been previously linked to the expression of the anti-apoptotic factors Bcl2L1(Bcl-xl) and Bcl2 respectively in murine liver (DelaCoste et al., 1999; Wakabayashi et al., 2000) , and we demonstrate herein that the increased levels of Pax3 and CyclinA1 correlate with increased transcript levels for both Bcl2 and Bcl2L1 in human SH-SY5Y cells. The observed increases in Bcl2 family members is in agreement with previous work that chronic LiCl and VPA treatment increased Bcl2 expression levels in rat brain and Bcl2 activity, both in SH-SY5Y cells in vitro (Yuan et al., 2001 ) and rat frontal cortex in vivo (Chen et al., 1999b) . The increased activity of these two anti-apoptotic factors would explain the observed decrease in caspase-3 activity in response to STS, and as inhibition of caspase activity has previously been linked to neuroprotection (Ray, 2006) we propose that this pathway is contributing to the ability of LiCl and VPA to act as neuroprotective agents. The protective ability of both LiCl and VPA against a number of other pro-apoptotic stimuli has been previously described, including ischemic stroke (Kim et al., 2007) and glutamate (Leng et al., 2008) , with GSK3? inhibition appearing to play a central role in both processes. The current work demonstrates that both LiCl and VPA have the ability to protect neural cells from STS-induced apoptosis and that this is also associated, at least in part, with inhibition of GSK3?.
In summary, we have identified Six1 as a signalling molecule through which LiCl and VPA protect neuroblastoma cells against STS-induced apoptosis, lending weight to the potential role of these therapeutics for neuroprotection. Moreover, we propose a hypothetical model, based upon existing literature, for their neuroprotective action, centred on the increased expression of the homoedomain protein Six1 by both drugs, and provide supporting evidence for it. More studies are needed to elucidate other pathways that also contribute to caspase-3 activation in these cells, and this may help in the development of new exciting strategies for neuroprotection. SH-SY5Y neuroblastoma cells were exposed to 3mM LiCl or 3mM VPA for 48 hours, with 1?M STS added for the final 16 hours as indicated. Cell death was then measured by LDH assay (A) and caspase-1/caspase-3 activity fluorimetric assay (B). For all experiments, data represents n=4±SEM, with statistical analysis via one-or two way ANOVA as applicable; *=p<0.01, **=p<0.05 and ***=p<0.01 and figure is representative of duplicate repeat experiments. (C) Pathway Architect software was used to develop a putative molecular mechanism by which LiCl and VPA could act inhibit apoptosis: LiCl and VPA inhibit, either directly or indirectly, GSK3?, which results in the observed increases in Pax3, Six1 and CyclinA1. Known target genes for Pax 3 and CyclinA1 are the anti-apoptotic proteins Bcl2L1 and Bcl2 respectively. Increased levels of these proteins result in blockade of caspase-3-mediated apoptosis and, ultimately, neuroprotection. SH-SY5Y neuroblastoma cells were exposed to VPA or LiCl at the indicated concentrations for 48 hours and then GSK3? phosphorylation status measured by ELISA (A). Pax3, CyclinA1 and Actin protein levels were measured by Western blotting, with TNT-expressed Pax3 and CyclinA1 used as a positive control. Protein expression was determined by densitometry (n=3), normalised to actin levels, and displayed as fold increase over vehicle control ±SEM (B). Bcl2 and Bcl2L1 transcript levels were measured by TaqMan Q-PCR (n=4 ±SEM) (C). Statistical analysis was via one-way ANOVA; *=p<0.01, **=p<0.05 and ***=p<0.01.
Figure 5: Six 1 is central to the LiCl and VPA-mediated neuroprotection against STS induced apoptosis in SH-SY5Y cells
Six1 was over-expressed in SH-SY5Y cells, which were then exposed to 1?M STS or medium for 16 hours and then cell death measured using LDH assay (A) and caspase-1/caspase-3 activity measured using a fluorimetric assay (B). In addition, SH-SY5Y neuroblastoma cells were exposed to 3mM LiCl or 3mM VPA for 48 hours, with 1?M STS added for the final 16 hours as indicated; wells were also transfected with siRNA targeted against Six1. Successful knockdown of Six1 was determined by quantitative PCR and Western blotting. An off-target siRNA (HCaRG) was included as a negative control (C). Cell death was measured using LDH assay, including siRNAs against both Six1 and HCaRG (D) . Each data point represents n=4 ±SEM. Statistical analysis was via one-or two way ANOVA as applicable; *=p<0.01, **=p<0.05 and ***=p<0.01 and is representative of at least duplicate repeat experiments.
